SequelSEC

Arcutis Biotherapeutics, Inc. ARQT

Pharmaceutical Preparations · CIK 0001787306 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$461.98M
Fiscal year ended 2026-06-30
Operating income
$34.25M
Fiscal year ended 2026-06-30
Free cash flow
$39.15M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$1.53BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$12.32Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue4.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity8.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin90.2%86th
CapEx / revenue0.2%14th
Revenue YoY growth91.3%82th
R&D / revenue20.5%22th
Operating margin-3.3%78th
Net margin-4.3%74th
FCF margin-1.7%70th
SBC / revenue10.7%37th
Current ratio3.17x44th
Long-term debt / equity0.57x54th

Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $461.98M and net income of $28.52M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Arcutis Biotherapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Arcutis Biotherapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$461.98M
Cost of revenue$41.10M
Gross profit$420.88M
Operating income$34.25M
Net income$28.52M
Research & development$91.04M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$779.00K
Diluted EPSUnavailable
Selling, general & administrative$297.60M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Arcutis Biotherapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$34.12M
Total assets$488.54M
Current assets$467.67M
Total liabilities$267.96M
Current liabilities$160.34M
Total equity incl. NCI$220.58M
Temporary (mezzanine) equityUnavailable
Inventory$38.88M
Accounts receivable$155.16M
GoodwillUnavailable
Long-term debt$101.95M
Accounts payable$6.60M

Cash flow

Arcutis Biotherapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$39.31M
Capital expenditures$158.00K
Investing cash flow-$85.98M
Financing cash flow$8.26M
Net change in cash-$38.62M
Stock-based compensation$43.55M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Arcutis Biotherapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$39.15M
Gross margin91.1%
Operating margin7.4%
FCF margin8.5%
SBC / revenue9.4%
Current ratio2.92x
Revenue YoY growth75.3%
Net margin6.2%
R&D / revenue19.7%
CapEx / revenue0.0%
Long-term debt / equity0.46x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ARQT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-10-28View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-06View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.